For more than 35 years, Haemonetics has been a global leader in blood processing technology. We have historically marketed Donor Products to blood and plasma collection centers. Donor products are automated blood and plasma collection systems and related consumables. We have also marketed Patient Products to the surgical suite for blood loss management for patients. Patient products include surgical blood salvage (or "autotransfusion") systems and related consumables.

But today, Haemonetics is providing more than just devices and consumables to our customers. Our product portfolio of devices and consumables, information technology platforms, and consulting services delivers a suite of business solutions for blood management.

Healthcare systems around the world want to ensure the best patient care at optimal cost. Blood management is often critical to ensuring best patient care and begins when the doctor determines if a patient will need a blood transfusion, and, if so, the best transfusion option for that patient. Effective blood management systems ensure that: 1) hospitals can improve patient care while operating efficiently and 2) blood collectors can ensure that the right blood is available at the right time for the right patient. Haemonetics provide customers with the tools necessary to understand the demand for blood, optimize scarce blood resources, insure regulatory compliance and a safe blood supply, and improve operational efficiency.

And we have proven experience. today, within the plasma industry, Haemonetics is providing business solutions for the plasma supply chain. We offer products and information technology platforms that help our customers manage processes from the point where the plasma donor enters the facility to the point that the end-product biopharmaceutical is given to the patient. We will leverage this expertise to strengthen our blood management solutions offerings for the blood supply chain.

Haemonetics' reputation for product innovation, technical expertise, and operational excellence gives us a highly defensible position in our traditional markets. By focusing on providing more value to our customer's critical initiatives, we are expanding our core business into a broader, diversified blood management solutions company.

Haemonetics is publicly traded as HAE on the New York Stock Exchange. We employ more than 1,800 people in 16 countries and market in over 50 countries. About 85% of revenues come from single-use consumables exclusively used with our devices. Almost half our revenues are derived from the Americas. The balance is derived nearly equally from Europe and Asia.